Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
Healthy Volunteers
ID05899387

Prospective, International Study to Identify Markers Predicting Seroma Development After Mastectomy With or Without Implant Reconstruction

Led by University Hospital Augsburg · Updated on 2025-02-28

2000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to identify markers that predict the risk of developing seromas, a common and serious complication after breast surgery, especially mastectomy. The study focuses on women with breast cancer or those at high risk undergoing mastectomy with or without implant reconstruction. Researchers are investigating the role of immune and inflammatory processes in seroma formation and analyzing tumor and surrounding tissue to understand possible specific immune responses related to cancer. Participants receive standard surgical treatments, including mastectomy and implant placement according to their clinical situation. During surgery, swabs are collected from the skin and surgical site. If seromas occur, further procedures like seroma puncture and ultrasound are performed to assess size and manage the condition. Blood samples are taken at scheduled times to study systemic immune responses. The study is international and includes multiple groups, such as breast cancer patients with different surgical plans and healthy women undergoing cosmetic or risk-reducing breast surgery. Participants are followed for six months, during which researchers collect clinical data, imaging, and laboratory samples to compare findings between those who develop seromas and those who do not. The main outcome is to identify patient groups at increased seroma risk. Secondary outcomes include comparing local and systemic immune responses and examining differences between cancer and non-cancer groups. This follow-up period allows detailed monitoring of seroma development and related immune processes to guide future personalized care strategies.

CONDITIONS

Brief Title

Seroma of the Mammary Gland

Who Can Participate

Age: 18Years +
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 18 years or older
  • Written informed consent provided
  • First diagnosis of breast cancer or ductal carcinoma in situ (DCIS) at any stage, with all histopathological subtypes
  • Planned surgical procedure including mastectomy (skin-sparing or simple) with or without implant or expander insertion
  • Healthy women at high risk for breast cancer planning bilateral risk-reducing mastectomy and implant reconstruction
  • Healthy women planning cosmetic breast implant surgery
Not Eligible

You will not qualify if you...

  • Age under 18 years
  • Male sex
  • Breast cancer patients planned for breast conserving therapy
  • Recurrent breast cancer disease
  • History of previous breast surgery
  • Diagnosis of lobular carcinoma in situ (LCIS) only
  • Pregnancy at the time of diagnosis
  • Known immunodeficiency

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery

Duration - Day of surgery

Participants undergo mastectomy with or without implant reconstruction, including intraoperative swab collection from the skin and surgical site.

1 visit (in-person)

Post-operative Follow-up

Duration - Up to 6 months

Participants are monitored for seroma development with blood sampling at defined time points. If a seroma occurs, participants undergo sonographic evaluation and may have seroma puncture if clinically needed.

Multiple visits for blood sampling and assessments as needed for seroma monitoring

Trial Site Locations

Total: 1 location

1

University Hospital Augsburg, Department of Gynecology and Obstetrics

Augsburg, Bavaria, Germany, 86156

Actively Recruiting

Loading map...

Research Team

N

Nina Ditsch, Prof.

M

Melitta Köpke, Dr. med.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

4

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here